Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-04-10
2007-04-10
Schnizer, Richard (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500, C514S723000, C514S772300, C568S624000
Reexamination Certificate
active
09457771
ABSTRACT:
The present invention relates to compositions and methods for delivery of antisense oligonucleotides or other nucleic acid sequences. The present invention comprises a delivery composition comprising an administerable admixture of an effective amount of a nucleic acid sequence and an effective amount of a surface active nonionic block copolymer having the following general formula:in-line-formulae description="In-line Formulae" end="lead"?HO(C2H4O)b(C3H6O)a(C2H4O)bHin-line-formulae description="In-line Formulae" end="tail"?wherein a is an integer such that the hydrophobe represented by (C3H6O) has a molecular weight between approximately 750 and approximately 15,000, preferably between approximately 2250 and approximately 15,000, more preferably between approximately 3250 and approximately 15,000, and b is an integer such that the hydrophile portion represented by (C2H4O) constitutes approximately 1% to approximately 50% by weight of the compound, preferably approximately 5% to approximately 25%.
REFERENCES:
patent: 2674619 (1954-04-01), Lundsted
patent: 2854378 (1958-09-01), Buckwalter
patent: 2979528 (1961-04-01), Lundsted
patent: 3022335 (1962-02-01), Lundsted
patent: 3036118 (1962-05-01), Jackson et al.
patent: 3089818 (1963-05-01), Stone
patent: 3140232 (1964-07-01), Noseworthy
patent: 3228834 (1966-01-01), Gans et al.
patent: 3450502 (1969-06-01), Hymes
patent: 3577522 (1971-05-01), Hymes
patent: 3590125 (1971-06-01), Hymes
patent: 3641240 (1972-02-01), Hymes et al.
patent: 3740421 (1973-06-01), Schmolka
patent: 3867521 (1975-02-01), Miskel et al.
patent: 3867533 (1975-02-01), Schmolka
patent: 3956259 (1976-05-01), Garcia et al.
patent: 4073886 (1978-02-01), Kehm
patent: 4100271 (1978-07-01), Krezanoski
patent: RE29909 (1979-02-01), Kurtz
patent: 4323560 (1982-04-01), Baschang et al.
patent: 4395393 (1983-07-01), Schmolka
patent: 4407790 (1983-10-01), Oakes et al.
patent: 4409209 (1983-10-01), Baschang et al.
patent: 4410660 (1983-10-01), Straus
patent: 4423038 (1983-12-01), Baschang et al.
patent: 4489158 (1984-12-01), Straus
patent: 4575484 (1986-03-01), Straus
patent: 4606918 (1986-08-01), Allison et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4772466 (1988-09-01), Allison et al.
patent: 4801452 (1989-01-01), Hunter et al.
patent: 4837014 (1989-06-01), Hunter et al.
patent: 4869900 (1989-09-01), Pozzi et al.
patent: 4873083 (1989-10-01), Hunter et al.
patent: 4879109 (1989-11-01), Hunter
patent: 4897263 (1990-01-01), Hunter
patent: 4937070 (1990-06-01), Hunter
patent: 4997644 (1991-03-01), Hunter
patent: 5017370 (1991-05-01), Hunter et al.
patent: 5028599 (1991-07-01), Hunter
patent: 5030448 (1991-07-01), Hunter
patent: 5032394 (1991-07-01), Hunter
patent: 5037644 (1991-08-01), Shaked et al.
patent: 5039520 (1991-08-01), Hunter
patent: 5041288 (1991-08-01), Hunter
patent: 5047236 (1991-09-01), Hunter et al.
patent: 5064643 (1991-11-01), Hunter et al.
patent: 5071649 (1991-12-01), Hunter
patent: 5078995 (1992-01-01), Hunter et al.
patent: 5080894 (1992-01-01), Hunter et al.
patent: 5089260 (1992-02-01), Hunter et al.
patent: 5221495 (1993-06-01), Cao
patent: 5262170 (1993-11-01), Anderson et al.
patent: 5372928 (1994-12-01), Miyamura
patent: 5376369 (1994-12-01), Allison et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5470568 (1995-11-01), Lee
patent: 5567859 (1996-10-01), Emanuele
patent: 5583032 (1996-12-01), Torrence
patent: 5656275 (1997-08-01), Wasmoen et al.
patent: 5674911 (1997-10-01), Emanuele et al.
patent: 5811088 (1998-09-01), Hunter et al.
patent: 27 08 152 (1977-09-01), None
patent: 0 000 704 (1979-02-01), None
patent: 0003999 (1979-02-01), None
patent: 0 003 999 (1979-09-01), None
patent: 0 011 237 (1980-05-01), None
patent: 0 049 422 (1981-09-01), None
patent: 0 103 290 (1983-09-01), None
patent: 0 121 752 (1984-10-01), None
patent: 0135376 (1990-07-01), None
patent: 2 081 436 (1971-01-01), None
patent: 60-105630 (1985-06-01), None
patent: PCT/US86/01747 (1986-08-01), None
patent: PCT/US87/01067 (1987-05-01), None
patent: WO 87/06836 (1987-11-01), None
patent: WO91/19794 (1991-12-01), None
patent: WO 92/16484 (1992-10-01), None
patent: WO 93/08845 (1993-05-01), None
patent: WO 99/39733 (1999-08-01), None
Verma et al. Nature 389: 239-242 , especially p. 239, Sep. 1997.
Anderson et al. Nature 392: 25-30, especially pp. 25 and 30, Apr. 1998.
Orkin (Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, see p. 1, item 3, and p. 9, Dec. 1995.
Simons et al (Sep. 1992) Nature 359:67-70.
Robinson-Benion et al (Antisense Research and Development, 1(1): 21-33, Feb. 1991.
Branch. Trends in Biochemical Sciences 23: 45-50, especially p. 45, col. 3. first para., p. 48, last para. through p. 49, Feb. 1998.
Crook In Basic Principles of Antisense Therapeutics, Springer-Verlag, Eds, New York, pp. 1 and 4. Jul. 1998Branch. Trends in Biochemical Sciences 23: 45-50, especially p. 45, col. 3. first para., p. 48, last para. through p. 49. Feb. 1998.Crook In Bas.
Donelly et al (J Immunol. Meth. 176:145-152, See p. 150, col. 1, first full paragraph, and col. 2, first full paragraph, Dec. 1994.
McCluskie et al (Molecular Medicine 5(5): 287-300, 1999.
Bioccha et al (Cytotechnology 5 S49-50, 1991).
Conforth, et al., “Antituberculous Effect of Certain Surface-Active Ethylene Ethers in Mice,”Chemical Abstracts,vol. 46, No. 2696 (1952).
Schmolka, “A Review of Block Polymer Surfactants,”Journal of the American Oil Chemists Society,vol. 54, No. 3, pp. 110-116 (1977).
Block and Graft Copolymerization,vol. 2, ed. by R.J. Ceresa, John Wiley & Sons (1976).
Matsukara, et al. “Phosphorothioate Analogs of Oligodeoxynucleotides: Inhibitors of Replication and Cytopathic Effects of Human Immunodeficiency Virus,”Proc. Natl. Acad. Sci. USA,vol. 84, pp. 7706 (1987).
Moore, et al., “Reduction of Splenic Vascular Resistance During Profusion by Pluronic® F-68,”Journal Surgical Research,vol. 8, pp. 563-566 (1968).
Snippe, et al., “Adjuvant Effect of Nonionic Block Polymer Surfactants in Humoral and Cellular Immuniology”,Int. Archs Allergy Appl. Immun.vol. 65, pp. 390-398 (1981).
Byars, et al., “Adjuvant formulation for us in Vaccines to Elicit Both Cell-mediated and Humoral Immunology”,Vaccine,vol. 5, pp. 223-228 (1987).
Paton, et al., “The Use of a Nonionic Detergent Added to Organ Perfusates,”Organ Perfusion and Preserv.,ed. by Norman, J.C. Appleton-Century-Crofts, pp. 105-120 (1968).
Technical Bulletin entitled “Pluronic® Block Copolymer Surfactants”.
Hunter, et al. “Nonionic Block Copolymers Surfactants as Immunological Adjuvants: Mechanisms of Action and Novel Formulations,”Immunological Adjuvants and Vaccines,ed. by Gregoriadis, G. et al., Plenun Publishing Corp., pp. 133-144 (1989).
Hunter, et al. “The Adjuvant Activity of Nonionic Block Polymer Surfactants. I. The Role of Hydrophile-Lipophile Balance,”J. Immun.,vol. 127, No. 3 (1981).
William, et al., “Modulation of Rat Granulocyte Traffic by a Surface Active Agent in Vitro and Bleomycin Injury,”Proceedings of the Society for Experimental Biology and Medicine,vol. 188, pp. 461-470 (1988).
Block, et al. “Acutely Traumatized Canine Ureter. Effects of Low Molecular Weight Dextran and Surfactant Pluronic® F-68,”Urology,vol. 3, No. 2, pp. 190-194 (1974).
Knize, et al. “Use of Antisludging Agents in Experimental Cold Injuries,”Surgery, Gynecology&Obstetric,vol. 129, pp. 1019-1026 (1969).
Gaehtgens, et al., “Disaggregation of Human Red Blood Cells by Various Surface-Active Agents as Related to Changes of Cell Shape and Hemolysis,”Act Heamat.vol. 53, pp. 82-89 (1975).
Lane, et al., “Reduction in the Toxicity of a Component of an Artificial Blood Substitute by Supercritical Fluid Fractionation,”Transfusion,vol. 28, pp. 375-378 (1987).
Atkinson, et al., “Ion Transport Mediated by Copolymers Composed of Polyoxyethylene and Polyoxypropylene,” pp. C20
Allaudeen Hameedsulthan S.
Emanuele R. Martin
Kousoulas Konstantin G.
LandOfFree
Therapeutic delivery compositions and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic delivery compositions and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic delivery compositions and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3775122